Letters to the Editor

Is Tacrolimus the Best Therapy for Atopic Dermatitis?


Am Fam Physician. 2003 May 1;67(9):1874.

to the editor: I read with interest the article, “Topical Tacrolimus: A New Therapy for Atopic Dermatitis,”1 because I recently saw a patient who experienced therapeutic failure with a $100 tube of tacrolimus for atopic dermatitis.

Because the response rate with tacrolimus is 27 to 36 percent compared with a 6 percent response rate for the vehicle alone, there is little doubt that tacrolimus works better than its vehicle alone. However, practicing physicians need to know whether tacrolimus works better than other available therapies, such as oral antihistamines, topical emollients, topical doxepin, and topical corticosteroids. This information would help physicians decide whether to order such an expensive new treatment or stay with the available remedies.


Russell JJ. Topical tacrolimus: a new therapy for atopic dermatitis. Am Fam Physician. 2002;66:1899–902.

Send letters to afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.

This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.



Copyright © 2003 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


May 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article